Evaluation of the Combination of Metformin and Rapamycin in an MPP+-Treated SH-SY5Y Model of Parkinson’s Disease
Metformin (MET) and rapamycin (RAPA) have been reported to protect against neurodegeneration in cellular and animal models of Parkinson’s disease (PD). MET, which is a first-line drug for type 2 diabetes, and RAPA are known as mTORC1 inhibitors. MET also acts as an AMPK activator, which leads to the...
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
Hindawi Limited
2023-01-01
|
| Edice: | Advances in Pharmacological and Pharmaceutical Sciences |
| On-line přístup: | http://dx.doi.org/10.1155/2023/3830861 |